ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktails aim to stall endometrial Cancer's return
Disease control OngoingThis study tests several drug combinations in women whose endometrial cancer has returned or not responded to treatment. The goal is to see if these combinations can slow or stop cancer growth better than current options. About 288 women are taking part, receiving different drugs…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:00 UTC
-
New drug combo shows promise for recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in about 31 people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. Participants must have ce…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 12:55 UTC
-
New hope for advanced endometrial cancer: Three-Drug cocktails tested
Disease control OngoingThis study tested three different combinations of chemotherapy and targeted drugs in 349 people with advanced or recurrent endometrial cancer. The goal was to see which combination worked best to stop the cancer from growing or spreading. Participants received one of three treatm…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 12:54 UTC
-
New combo therapy shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 adults…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 12:45 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or returned and is no longer responding to standard chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. Par…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 17, 2026 12:45 UTC
-
New drug combo shows promise for tough endometrial cancer
Disease control OngoingThis study tests whether adding an experimental drug (BMS-986205) to the immunotherapy nivolumab can shrink tumors or prevent cancer from coming back in people with recurrent endometrial cancer. About 24 participants will receive either nivolumab alone or the combination. The goa…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC